Skip to content
ClinCalc Pro
Menu
Opioid + paracetamol combination

Dihydrocodeine with paracetamol

Brand names: co-dydramol, Galake, Remedeine

Used in: Burns

This is a fixed-dose combination of the weak opioid dihydrocodeine with paracetamol (co-dydramol), used for moderate pain not relieved by paracetamol alone.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Dihydrocodeine is a mu-opioid receptor agonist providing central analgesia, while paracetamol contributes analgesic and antipyretic effects through poorly understood central mechanisms; the two act by complementary routes.

Prescribing in practice

  • Because the product contains paracetamol, avoid concomitant paracetamol from other sources to prevent inadvertent overdose and hepatotoxicity.
  • The opioid component carries risks of respiratory depression, constipation, dependence and tolerance, with additive sedation alongside alcohol and other CNS depressants.
  • Use reduced doses and caution in the elderly and in hepatic or renal impairment, and prescribe for the shortest effective period.

Monitoring

Monitor pain control, sedation, bowel function and total daily paracetamol intake from all sources during use.

Counselling the patient

  • Do not take any other paracetamol-containing products alongside this medicine.
  • Avoid alcohol and report excessive drowsiness or slow breathing.
  • Use measures to prevent constipation and do not exceed the stated dose.

Evidence & guidelines

Compound analgesics combining a weak opioid with paracetamol are recognised options for moderate pain when simple analgesia is insufficient.

Reference: NICE NG140; NICE NG193; FPM Opioids Aware; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.